You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The latest regulatory news and FDA approvals.
Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.
The company also plans to submit a new drug application for avapritinib in mainland China in the first half of this year.
The approval limits the drug's use to patients who are refractory or intolerant to standard-of-care treatments and contains warnings about the risk of interstitial lung disease.
The Chinese drug evaluation agency has granted the investigational new drug clinical trial authorization to taletrectinib in NRTK- and ROS1-mutated cancer patients.
The drug, Amelie, will be for the second-line treatment of EGFR T790-mutated non-small cell lung cancer.